Jeffrey Dierks - 28 Feb 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
Chief Commercial Officer
Signature
/s/ Christian Ulrich, Attorney-in-fact for Jeffrey Dierks
Issuer symbol
HRMY
Transactions as of
28 Feb 2022
Net transactions value
-$315,604
Form type
4
Filing time
02 Mar 2022, 15:05:45 UTC
Previous filing
18 Feb 2022
Next filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $240,984 +10,041 $24.00 10,041 28 Feb 2022 Direct
transaction HRMY Common Stock Sale $401,653 -10,041 -100% $40.00 0 28 Feb 2022 Direct F1, F2
transaction HRMY Common Stock Options Exercise $40,023 +4,869 $8.22* 4,869 01 Mar 2022 Direct
transaction HRMY Common Stock Sale $194,958 -4,869 -100% $40.04 0 01 Mar 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -10,041 -7.1% $0.000000 130,556 28 Feb 2022 Common Stock 10,041 $24.00 Direct F4
transaction HRMY Stock Option Options Exercise $0 -4,869 -25% $0.000000 14,607 01 Mar 2022 Common Stock 4,869 $8.22 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.06. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.74 to $40.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vests in five equal annual installments beginning on August 21, 2021.
F5 The stock option vests in five equal annual installments beginning on March 4, 2021